CLDXCelldex Therapeutics, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+107.6% YoY

Gross Profit

-$35M-473.4% margin

Operating Income

-$63M-854.1% margin

Net Income

-$60M-805.9% margin

EPS (Diluted)

$-2.02

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$42M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$236M

Total Liabilities

$26M

Stockholders' Equity

$209M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$4M	+107.6%
Gross Profit	-$35M	-$39M	+10.2%
Operating Income	-$63M	-$55M	-15.1%
Net Income	-$60M	-$51M	-17.5%

CLDX FY 2020 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena